PMV Pharmaceuticals (PMVP)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	49.63 mm	49.63 mm	49.63 mm	49.63 mm	49.63 mm	49.63 mm
Cash burn (monthly)	(no burn)	270.58 k	7.30 mm	6.60 mm	5.61 mm	3.89 mm
Cash used (since last report)	n/a	1.37 mm	37.07 mm	33.53 mm	28.52 mm	19.78 mm
Cash remaining	n/a	48.26 mm	12.56 mm	16.10 mm	21.11 mm	29.85 mm
Runway (months of cash)	n/a	178.3	1.7	2.4	3.8	7.7

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

PMVP institutional ownership history Ownership history

84.1% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	76	95	-20.0%
Opened positions	5	24	-79.2%
Closed positions	24	27	-11.1%
Increased positions	23	25	-8.0%
Reduced positions	30	30	–

13F shares	Current	Prev Q	Change
Total value	54.81 bn	61.22 bn	-10.5%
Total shares	43.50 mm	44.99 mm	-3.3%
Total puts	1.70 k	100.00	+1600.0%
Total calls	3.00 k	400.00	+650.0%
Total put/call ratio	0.6	0.3	+126.7%

Largest owners	Shares	Value	Change
Orbimed Advisors	6.48 mm	$9.65 bn	0.0%
ArrowMark Colorado	3.65 mm	$5.43 bn	+30.0%
Sio Capital Management	3.21 mm	$4.79 bn	+18.7%
Euclidean Capital	2.63 mm	$3.92 bn	0.0%
Alkeon Capital Management	2.34 mm	$3.49 bn	-0.1%
Vanguard	2.28 mm	$3.40 bn	-0.1%
Acadian Asset Management	2.08 mm	$3.09 mm	0.0%
Partner Fund Management	2.01 mm	$3.00 bn	+57.7%
BML Capital Management	1.69 mm	$2.52 bn	+29.0%
Interwest Partners X	1.61 mm	$0.00	0.0%

Largest transactions	Shares	Bought/sold	Change
BLK BlackRock	0.00	-1.16 mm	EXIT
BlackRock	1.14 mm	+1.14 mm	NEW
ArrowMark Colorado	3.65 mm	+842.51 k	+30.0%
Partner Fund Management	2.01 mm	+735.58 k	+57.7%
Citadel Advisors	1.06 mm	-660.78 k	-38.5%
Sio Capital Management	3.21 mm	+505.83 k	+18.7%
Opaleye Management	0.00	-475.00 k	EXIT
BCS Barclays	30.25 k	-434.70 k	-93.5%
Millennium Management	363.97 k	-394.77 k	-52.0%
BML Capital Management	1.69 mm	+379.38 k	+29.0%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

PMVP insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
3 Jan 25	Mack David Henry	Common Stock	Option exercise	Acquire M	No	No	0.53	17,709	9.39 k	551,919
3 Jan 25	Mack David Henry	Employee Stock Option Common Stock	Option exercise	Dispose M	No	No	0.53	17,709	9.39 k	0
3 Dec 24	Mack David Henry	Common Stock	Option exercise	Acquire M	No	No	0.53	91,750	48.63 k	534,210
3 Dec 24	Mack David Henry	Employee Stock Option Common Stock	Option exercise	Dispose M	No	No	0.53	91,750	48.63 k	17,709
11 Sep 24	Michael Carulli	Common Stock	Sell	Dispose S	No	No	1.5036	2,891	4.35 k	88,395
11 Sep 24	Deepika Jalota	Common Stock	Sell	Dispose S	No	No	1.5036	7,218	10.85 k	118,283
13 Aug 24	Mack David Henry	Employee Stock Option Common Stock	Grant	Acquire A	No	No	1.48	330,000	488.40 k	330,000
13 Aug 24	Mack David Henry	Employee Stock Option Common Stock	Sale back to company	Dispose D	No	No	5.7	330,000	1.88 mm	0
13 Aug 24	Mack David Henry	Employee Stock Option Common Stock	Grant	Acquire A	No	No	1.48	384,184	568.59 k	384,184
13 Aug 24	Mack David Henry	Employee Stock Option Common Stock	Sale back to company	Dispose D	No	No	16.29	249,600	4.07 mm	0

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Press releases

From Benzinga Pro

PMV Pharmaceuticals to Participate at Upcoming Investor Conferences

11 Feb 25

PRINCETON, N.J., Feb. 11, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting